Puma Biotechnology/$PBYI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Puma Biotechnology
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Ticker
$PBYI
Sector
Primary listing
Employees
179
Headquarters
Website
PBYI Metrics
BasicAdvanced
$305M
9.84
$0.61
1.28
-
Price and volume
Market cap
$305M
Beta
1.28
52-week high
$7.68
52-week low
$2.58
Average daily volume
451K
Financial strength
Current ratio
2.002
Quick ratio
1.861
Long term debt to equity
3.613
Total debt to equity
21.901
Interest coverage (TTM)
5.63%
Profitability
EBITDA (TTM)
47.437
Gross margin (TTM)
74.53%
Net profit margin (TTM)
13.62%
Operating margin (TTM)
16.33%
Effective tax rate (TTM)
13.05%
Revenue per employee (TTM)
$1,280,000
Management effectiveness
Return on assets (TTM)
10.85%
Return on equity (TTM)
27.97%
Valuation
Price to earnings (TTM)
9.836
Price to revenue (TTM)
1.314
Price to book
2.32
Price to tangible book (TTM)
3.4
Price to free cash flow (TTM)
7.191
Free cash flow yield (TTM)
13.91%
Free cash flow per share (TTM)
0.834
Growth
Revenue change (TTM)
-0.91%
Earnings per share change (TTM)
-1.61%
3-year revenue growth (CAGR)
0.05%
3-year earnings per share growth (CAGR)
2,302.29%
10-year earnings per share growth (CAGR)
-22.14%
What the Analysts think about PBYI
Analyst ratings (Buy, Hold, Sell) for Puma Biotechnology stock.
PBYI Financial Performance
Revenues and expenses
PBYI Earnings Performance
Company profitability
PBYI News
AllArticlesVideos
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results
Business Wire·1 month ago
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 month ago
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Puma Biotechnology stock?
Puma Biotechnology (PBYI) has a market cap of $305M as of March 20, 2026.
What is the P/E ratio for Puma Biotechnology stock?
The price to earnings (P/E) ratio for Puma Biotechnology (PBYI) stock is 9.84 as of March 20, 2026.
Does Puma Biotechnology stock pay dividends?
No, Puma Biotechnology (PBYI) stock does not pay dividends to its shareholders as of March 20, 2026.
When is the next Puma Biotechnology dividend payment date?
Puma Biotechnology (PBYI) stock does not pay dividends to its shareholders.
What is the beta indicator for Puma Biotechnology?
Puma Biotechnology (PBYI) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.